Cancer progression in the kidney and prostate: vital roles of sphingolipids in chemotherapy.
Radin
Norman S
NS
Mental Health Research Institute, University of Michigan, Ann Arbor, Michigan, USA.
D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D003131:Combined Modality Therapy; D018450:Disease Progression; D005978:Glutathione / Q000378:metabolism / Q000502:physiology; D006133:Growth Substances / Q000494:pharmacology / Q000502:physiology; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology*; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology*; D013107:Sphingolipids / Q000378:metabolism / Q000502:physiology*; D013739:Testosterone / Q000494:pharmacology / Q000502:physiology; D014747:Vinblastine / Q000627:therapeutic use
D000726:Androgen Antagonists; D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D006133:Growth Substances; D013107:Sphingolipids; D013739:Testosterone; D014747:Vinblastine; D005978:Glutathione